The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ray, Thank you. I have thought that for awhile. I have not done much investigation into the various applications, however, I think they will come. All the more reason for there to be someone who knows how to communicate that value to those who are interested in this arena.
(I am struggling to understand why some are continually selling at such a low value when leaving the small sums they are trading in place for two years really would not make much difference. With £3 to £8/ trade costs, it seems pointless.)
BS, yes, I spotted it was from 8 years ago, thanks for following up.
Inan,
Where do you find these little gems, could do with a project, perhaps for me to start would be a bsa bantam!
ATB
“ i presume you are happy to wait ... for the trial to progress .”
We don’t really have a choice really do we?
Bunsie
Bought another Bike yesterday to add to the collection .... Mint Triumph 955i Daytona ... a little pocket rocket ..
Ruck
Well the Good news you have not sold, so i presume you are happy to wait ... for the trial to progress .
meantime ..
Cricket and F1 ..
LL, I think you will find potential outside cancer for all 3 of Scancell's platforms.
With immunobody any condition that can be helped by a well-targeted CD4/CD8 attack. You certainly get the impression that the role of TCells in clearing viruses is not as well researched as it is in cancer.
With moditope, any condition that exhibits autophagy and results in presentation of citrillunated and/or homocitrullinated epitopes. Lindy, with her background in biochemistry, is not content to just sit back and say "it works" she has also researched the biochemical processes that take place leading to the all important expression of those epitopes.
That is exactly why Karolinska are interested in how moditope works. It appears not so much for moditope itself but the aim may be to break a link in that chain of processes to help prevent autoimmune diseases.
With Avidimab, it is possibly any mAB. Avidity for mABs is not confined to treatment of cancer.
Inan,
I was referring to clinical progress of SCIB1 in the treatment of melanoma in reference to LL’s question regarding the announcement of the clinical trial of SCIB1 for the treatment of melanoma “first patient dosed” RNS.
This trial produced some compelling data but finished several years ago, since which time there has been no further patients dosed. We are eagerly awaiting the first patient dosed in the SCIB1 combo trial with Keytruda.
If you could highlight any significant clinical progress with SCIB1 in the treatment of melanoma that I may have overlooked, please let me know.
The point being, I don’t think it is particularly helpful to advertise something that started 10 years ago that has not gone anywhere (yet). One would be forgiven for asking “was it any good?”, “why hasn’t it gone anywhere?
Let’s have some “New” news.
LochnivarLass,
Sorry, just to be clear, you do realise that the RNS posted by Ray refers to the original SCIB1 trial which was completed several years ago? Apologies if I've got it wrong, but your posts suggested you might think it was the current trial .
Forgotten .. by some
SCIB2 ............ complete with new delivery system which we assume will be carried forward with other immunobody products in development
hasn't progressed for years is just not true
Agree. Even though I have been through their media page before, it is very easy to get distracted. However, repeating the sound bite frequently will not do us any harm if we get to market / land a deal sooner rather than later.
LL,
The SCIB1 melanoma trial and positive results were well publicised at the time.
But that is a long time ago. What we need now is news of further progress which to date has been a long time coming.
Having a platform that hasn’t progressed for years is perhaps not a message you want to broadcast to potential investors.
Ray, this is the first time I've seen this.... I keep wondering why Scancell is the best kept secret on the AIM market.
Way back in 2010
https://www.scancell.co.uk/scib1-phase-i-trial-commences-first-patient-treated
"The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases."
Well, now Lindy has a chance to prove it.